Circadian Rhythm Sleep Disorders Market Analysis & Forecast: 2026-2033
The Circadian Rhythm Sleep Disorders Market size is anticipated to grow at a CAGR of 6.8% with USD 2.7 Bn in 2026 and is expected to reach USD 4.23 Bn in 2033. The primary drivers are largely defined by the rising burden of sleep deprivation, shift work disorder, and circadian misalignment. Some of the other factors are increasing night-shift employment, growing screen exposure, higher adoption of melatonin and light therapy, and greater diagnosis of sleep-related productivity loss. The CDC reported that 30.5% of U.S. adults slept less than seven hours in 2024, thereby supporting the demand for Circadian Rhythm Sleep Disorders treatment solutions.
On the basis of treatment type, the melatonin segment is projected to account for the largest Circadian Rhythm Sleep Disorders Market share of 55.8% in 2026. The segment’s growth is owing to its central role in regulating the human sleep‑wake cycle and the widespread prevalence of sleep disturbances.
According to the CDC NCHS Data Brief (2026), nearly 60.2% of adults aged 20 and above reported using any dietary supplement in August 2023, which includes melatonin. This highlights the broad consumer reliance on the non‑prescription sleep‑related products.
In addition, the CDC FastStats data show that around 36.8% of adults reported not getting enough sleep, thereby underscoring the persistent public health burden propelling the demand for circadian rhythm interventions.
A key development in the last few years is its ongoing Phase 3 clinical trial evaluating tasimelteon versus placebo in Delayed Sleep‑Wake Phase Disorder (DSWPD), with estimated completion in mid‑2026, which could expand formal indications if successful.
To learn more about this report, Request Free Sample
On the basis of application type, the delayed sleep phase disorder segment lead with a major 32.4% share in 2026. The segment’s growth is owing to the prevalence data and rising clinical focus.
Government-linked health sources report that approximately 3% of the general population meets diagnostic criteria for DSPD, with incidence particularly high among adolescents and young adults.
Among individuals presenting with insomnia, nearly 10% are likely to have DSPD, thereby underscoring its clinical significance. The therapeutic approaches are diversifying beyond traditional melatonin treatments, thereby reflecting increased research in alternative interventions.
In 2026, a Phase 4 study of lemborexant, an orexin receptor antagonist, was completed to evaluate its effect on shortening sleep onset latency in DSPD patients. These developments highlight the growing emphasis on non-melatonin therapies and personalized management strategies.
The shifting lifestyles and irregular work schedules in the United States are substantially increasing the prevalence of circadian misalignment and sleep disruptions, which in turn is transforming the Circadian Rhythm Sleep Disorders market.
According to the National Center for Health Statistics’ 2024 National Health Interview Survey, nearly 18.1% of adults reported having trouble staying asleep most days or every day, a well‑documented risk factor for circadian rhythm disorders.
Complementing these trends, the CDC data released on April 2026, showed that 12.9% of adults used , thereby reflecting a growing therapeutic engagement for sleep‑related disturbances tied to circadian dysfunction. These behavioral and healthcare utilization patterns are prompting a greater demand for targeted diagnostics as well as interventions.
In clinical developments, an ongoing U.S. trial (NCT03715465) is investigating whether measuring intrinsic circadian clock markers can improve treatment outcomes for delayed sleep
The wearable and AI‑enabled biosensing technologies for circadian assessment and monitoring represent a major breakthrough in the market.
The public health burden of these disorders is very high. According to the U.S. National Heart, Lung, and Blood Institute, an estimated 50, thereby highlighting the persistent unmet need for effective solutions.
In response, the innovators are leveraging advanced sensor fusion and artificial intelligence to capture objective physiological and behavioral patterns in real time, thereby allowing for personalized circadian profiling and dynamic intervention.
A notable recent development is a multicenter prospective study (ClinicalTrials.gov NCT07582809), first posted on May 2026, which is evaluating the long
These advancements underscore the growing interest from clinicians, researchers, and regulators in integrating wearable sleep tech with AI to better assess and manage circadian rhythm disturbances.
|
Current Event |
Description and its Impact |
|
U.S. FDA Final Guidance on Digital Therapeutics Regulation
|
|
|
EU Health Technology Assessment (HTA) Reform Implementation
|
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
The North America region accounts for 36.2% of the market share in 2026. The region’s growth is owing to a combination of high prevalence of circadian rhythm disruptions, increasing awareness of sleep health, and robust clinical research activity.
The U.S. government data from 2024 indicate that nearly 37.6% of workers sleep fewer than seven hours per night. The night shift employees disproportionately get affected at 61.8%, thereby highlighting the widespread impact of circadian misalignment.
In addition, about 18.5% of night shift workers report insomnia symptoms associated with disrupted circadian rhythms, thereby underscoring the clinical need for targeted interventions.
A relevant development in the market is ongoing clinical research such as the Healthy Patterns Sleep Study (NCT03682185), exploring behavioral and activity
Asia Pacific is expected to witness strong growth in Circadian Rhythm Sleep Disorders Market over the forecast period. The region’s growth is owing to the to a combination of high prevalence of sleep disorders, expanding awareness of sleep health, and robust healthcare infrastructure.
Regional studies indicate that shift work disorder affects 46.5% of nurses in countries with rotating three-shift hospital models, reflecting a significant workforce burden. Broader economic and industrial evolution has increased night-shift operations across major hubs, with 36.1% of employees in industrialized nations like China and South Korea regularly engaged in shift work, exposing them to circadian misalignment risks. In addition, the insomnia prevalence in Australia ranges from 13.1% to 23.2%, thereby demonstrating a growing need for clinical interventions.
In October 2025, P. D. Hinduja Hospital launched a specialised Sleep Clinic in Asia Pacific, thus providing both comprehensive medical and psychological care. The clinic addresses insomnia,
The United States Circadian Rhythm Sleep Disorders Market is experiencing growth owing to the high prevalence among night or irregular shift workers and continued clinical developments. Approximately 9% of Americans engaged in night or irregular shifts are estimated to have shift work sleep disorder, thereby highlighting a substantial affected population with circadian misalignment.
In terms of treatment advancements, a Phase 3 clinical trial evaluating tasimelteon (HETLIOZ®) for delayed sleep
China’s Circadian Rhythm Sleep Disorders Market is driven by a high prevalence of sleep problems, with over 300 million adults affected by insomnia and circadian rhythm disturbances. These disorders substantially impact both the health as well as the quality of life.
In May 2025, Eisai Co., Ltd. secured the regulatory approval and announced the planned China launch of DAYVIGO (lemborexant). It is a dual orexin receptor antagonist which modulates sleep–wake rhythm in adults with insomnia. This marks a significant expansion of treatment options in the Chinese sleep disorder therapeutics landscape.
Some of the major key players in Circadian Rhythm Sleep Disorders Market are Vanda Pharmaceuticals, Aeroflow, Inc., Cephalon, Inc., Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., The Sunbox Company, Verilux, Inc., Northern Light Technologies, Koninklijke Philips N.V., and Amjo Corp.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.7 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.8% | 2033 Value Projection: | USD 4.23 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Vanda Pharmaceuticals, Aeroflow, Inc., Cephalon, Inc., Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., The Sunbox Company, Verilux, Inc., Northern Light Technologies, Koninklijke Philips N.V., and Amjo Corp. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
